FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 625 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas January 20, 2021 Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients... March 27, 2023 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 Load more HOT NEWS Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Junk food marketing restrictions: so near and yet so far FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ
